Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold
.10 gm dose If 1 mL=100 units, then a .10mg dose (0.10 / 10) 100 = 1 unit
As more Americans become aware of the benefits and seek out weight-loss medications, the growing demand is becoming increasingly tangible
It aligns with cortisol peaks and prepares the body for daytime demands, offering steady, clean energy
When the proportion of bile salts and/or phospholipids decreases and cholesterol levels remain too high, the bile thickens, making it sluggish
It shows a positive impact in the treatment and prevention of diabetes